Skip to content
ADMETatlas
peptide evidence atlas
Home
About
Home

Browse

PeptidesProductsEvidenceContext signalsDescriptors

Developability

ProfileComparator

Resources

ManualExplanationsStatisticsDownloadLicenseAbout
  1. Home
  2. Peptides
  3. Tirzepatide
Peptide·modified or textual

Tirzepatide

ATLPC0005195

Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS

Routes
Compare in workbenchDownload releaseAPI JSON
  • Length
    39 aa
On this page
  • 01 Sequence & molecular identity
  • 02 Physicochemical profile
  • 03 Exposure / Absorption
  • 04 Distribution / Barrier
  • 05 Excretion / Persistence
  • 06 Evidence landscape
  • 07 Product context
  • 08 Identity & reference map
  • 09 Data access & reproducibility
Coveragecounts only · not riskATLPC0005195
  • Measurements
    37
  • Endpoints
    8
  • Domains
    3/5
  • Products
    1
  • No matrix stability evidence
  • 20 clearance measurements
  • Product-level review pending
  • No sequence liability cues
Jump to domain

Open the matching evidence section below

All evidence index · 37
Exposure / Absorption
11 measurements
Distribution / Barrier
6 measurements
Metabolic & Proteolytic Stability
No evidence
Excretion / Persistence
20 measurements
Toxicity / Safety
No evidence
01

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

·
Identity view

A peptidoform is one specific molecular form of the peptide — its sequence plus the modifications at given positions (HUPO-PSI term). This view preserves the reported terminal groups, residue modifications, and stereo markers from the source notation.

Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Identity summarySpecific molecular form represented
Identity status
Specific molecular form represented
Residues
39
Peptidoform features
2
Documented molecular forms
1
Representations
2
Documented molecular forms1 form linked to this peptide identity
FormTopologyModificationsConnectionsRepresentationsMeasurements
ATLPF0005666———Notation only18
Residue view
Residue display
39 residues
Y1X2AibE3G4T5F6T7S8D9Y10S11I12X13AibL14D15K16I17A18Q19K20A21F22V23Q24W25L26I27A28G29G30P31S32S33G34A35P36P37P38S39
Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

Non-standard residue tokenpos 2
Aib

Alpha-aminoisobutyric acid was reported as a non-standard residue. It is shown as X in the parent-residue display.

Non-standard residue tokenpos 13
Aib

Alpha-aminoisobutyric acid was reported as a non-standard residue. It is shown as X in the parent-residue display.

Reported sequence notation was converted to parent-residue display for visualization; the original notation remains shown below.

Structure & chemistry

·
Chemical representationsequence / HELM only
Representation class

How the current release can interpret this identity chemically.

modified or textual
Parent-residue sequence

Residue string used for positional interpretation when available.

YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
HELM

Polymer notation for modified peptide representation when available.

Not available
SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available
No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure referencesnone attached
3D structure not available

A 3D structure isn't available for this peptide in the current release. Chemistry and topology fields remain available when represented by sequence, HELM, or SMILES.

Covalent topology & modificationsnone
Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

02

Physicochemical profile

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Physicochemical descriptors unavailable

These descriptors require a standard parent-residue sequence. The module remains visible so modified or unresolved identities are not forced into unreliable computed values.

03

Exposure / Absorption

11 records

What evidence describes systemic exposure or absorption?

Evidence records
11
Complete canonical measurements and observations attached to this domain.
Endpoint scope
4
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeBioavailabilityAUCCmaxTmax
Loading 11 Exposure / Absorption records…
04

Distribution / Barrier

6 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records
6
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
0
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
1
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopePlasma protein bindingVd
Loading 6 Distribution / Barrier records…
Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA
0

artificial membrane

Caco-2
0

cell monolayer

MDCK
0

cell monolayer

RRCK
0

cell monolayer

BBB
0

barrier evidence

05

Excretion / Persistence

20 records

What evidence describes clearance or persistence?

Evidence records
20
Complete canonical measurements and observations attached to this domain.
Endpoint scope
2
Formal ADMET endpoints represented for this peptide.
Matched-context in preview
9
Quantitative results that may be analysed only with scientifically compatible records.
Reported results in preview
9
Qualitative, narrative, or review-first results interpreted in their source context.
Endpoints in scopeHalf LifeClearance
Loading 20 Excretion / Persistence records…
06

Evidence landscape

37 records

Cross-domain evidence distribution and measurement-level detail. 20 of 37 evidence records are included in the profile preview; the full index is loaded below.

Loading 37 measurements…
07

Product context

1 products

Product-level route, label, and clinical context that frames peptide-level evidence. A peptide-level summary only; product pages keep the full drilldown.

·
Summary1 linked product
Linked products
1
Label context
1
Clinical trials
61
Safety label cues
None
Linked products1 shown

Tirzepatide

MOUNJAROZEPBOUND
Peptide-product match
Unique peptide match
Route / product class
MOUNJARO (tirzepatide) injection, for subcutaneous use, contains tirzepatide, a once weekly GIP receptor and GLP-1 receptor agonist. It is a 39-amino-acid modified peptide based on the GIP sequence. Tirzepatide contains 2 non-coded amino acids (aminoisobutyric acid, Aib) in positions 2 and 13, a C-terminal amide, and Lys residue at position 20 that is attached to 1,20-eicosanedioic acid via a linker.
Clinical context
61 trial records · 39 exact intervention matches · 10 with results · latest 2026-04-21
Label safety context
Label linked
View product
08

Identity & reference map

37 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

·
Summary10 reference groups
Identity type
reported modified sequence
Reported notation
1
Reference groups
10
Measurements
37
ATL peptide ID
ATLPC0005195
Identity concordance
Identity concordance
Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 37
Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

2 / 37
Different notation

Reported notation does not resolve to the current display sequence.

0 / 37
Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

35 / 37
Reported sequence notation
Parent-compatible2 references
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPS
Current identity
Y-Aib-EGTFTSDYSI-Aib-LDKIAQKAFVQWLIAGGPSSGAPPPS
Reported names
No distinct human-readable aliases are exposed.
Reference map10 reference groups
Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

ReferenceSupportsReported identityRecords
Reference
Open
Persistence
Half Life
No reported alias
6 identity
6 evidence
Reference
Open
Persistence
Half Life
No reported alias
4 identity
4 evidence
Reference
Open
Identity only
No reported alias
8 identity
0 evidence
Reference
Open
Persistence
Half Life
No reported alias
3 identity
3 evidence
Reference
Open
Persistence
Half Life
No reported alias
3 identity
3 evidence
Reference
Open
Identity only
No reported alias
6 identity
0 evidence
Source record
Open
DistributionExposure
Bioavailability, Plasma Protein Binding
No reported alias
YXEGTFTSDYSIXLDKIAQKAFVQWLIAGGPSSGAPPPSparent-compatible
2 identity
2 evidence
Reference
Open
Identity only
No reported alias
3 identity
0 evidence
Reference
Open
Persistence
Half Life
No reported alias
1 identity
1 evidence
Reference
Open
Persistence
Half Life
No reported alias
1 identity
1 evidence
09

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

·
Record scopePublic release
ATL peptide ID
ATLPC0005195
Identity type
reported modified sequence
ADMET endpoints
8
Evidence records
37
Reference groups
10
Release view
Public release
Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements
Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint
GET /api/v1/peptides/ATLPC0005195
open
curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0005195' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'
ADMETatlas
peptide evidence atlas

ADMETatlas is an open, curated atlas of ADMET evidence for therapeutic peptides — spanning developability, membrane permeability and blood–brain-barrier transport, immune-recognition context, and approved-product context. Every measurement stays linked to its original source, with stable identifiers and transparent curation, so results can be traced, cited, and reproduced.

Browse
PeptidesProductsEvidenceContext signalsDescriptors
Resource
DevelopabilityComparatorManualExplanationsStatisticsDownloadAbout
Stack
  • RDKit
  • Mol*
  • Python
  • FastAPI
  • PostgreSQL
  • Next.js
  • React
  • TypeScript
  • Tailwind CSS
  • Apache ECharts
© 2026 ADMETatlas, an academic peptide ADMET evidence atlas.